Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

58P - Spectrum of germline pathogenic mutations in 1087 Chinese patients with biliary tract cancer

Date

10 Sep 2022

Session

Poster session 13

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

jun Shen

Citation

Annals of Oncology (2022) 33 (suppl_7): S19-S26. 10.1016/annonc/annonc1036

Authors

J. Shen1, R. Kong2, D. Guo2, S. Chen3, T. Han2, M. Wang2, G. Lu2, W. Deng3, R. Ding4, F. Bu4

Author affiliations

  • 1 Department Of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438 - Shanghai/CN
  • 2 The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., 210000 - Nanjing/CN
  • 3 Bioinformatics Department, Jiangsu Simcere Diagnostics Co., Ltd., 210000 - Nanjing/CN
  • 4 Operations Department, Jiangsu Simcere Diagnostics Co., Ltd, 210000 - Nanjing/CN
More

Abstract 58P

Background

Biliary tract cancer(BTC) is a heterogeneous solid tumor with poor prognosis and the incidence of BTC is rising globally. In recent years, researchers have tried to identify therapeutic targets of BTC patients (pts), but have ignored the germline mutation landscape. Herein, we will present an overview regarding the status of pathogenic germline mutations in Chinese BTC pts.

Methods

We retrospectively analyzed 1087 Chinese BTC samples which underwent hybridization capture based next-generation sequencing (NGS) to investigate the prevalence of germline mutations. The pathogenicity of germline mutations (including SNV, small INDEL) was categorized based on American College of Medical Genetics and Genomics (ACMG) guidelines.

Results

Of 1087 BTC pts, 94 (9.84%) pts were identified to carry 98 pathogenic variants(P) or likely pathogenic variants(LP) in 112-cancer predisposition gene panel, 4 pts carried 2 germline mutations. The rest 994 BTC pts were Non-P/LP group. No significant differences were found between P/LP and Non-P groups in age (average age: 60.4 vs 61.8, p=0.2). Most P/LP mutations were loss of function (LOF) variants. The highest prevalence of germline mutation was found in BRCA1/2 (n=16, 1.47%), PALB2(n=10, 0.92%), MUTYH(n=6, 0.55%), FANCA (n=5, 0.46%) and FANCD2(n=5, 0.46%). On the contrary, somatic mutation analysis found that P/LP group exhibited significantly high tumor mutation burden (TMB) compared with non-p/LP group (average TMB: 9.50 vs 3.98, p < 0.001). 71 BTC pts (6.7%) had germline mutations in the DNA-damage repair (DDR) signal pathway, of which homologous recombination (HR) genes accounted for the highest proportion. There was no age difference between DDR P/LP and non-DDR P/LP group (average age: 60.6 vs 61.8, p=0.34). Compared with non-DDR P/LP group, individuals with DDR P/LP group tended to have a higher level of TMB (average TMB: 10.66 vs 4.01, p < 0.001).

Conclusions

This research elucidated the spectrum of pathogenic germline mutations in Chinese BTC to identify candidate genes for hereditary BTC. In addition, the occurrence of DDR P/LP germline mutations were significantly correlated with a higher TMB, which could lead to an improvement in the personalized treatment for BTC pts.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.